Does seem odd Mon - especially when you consider that most of the new shares have been taken up by existing holders.
We are right on the cusp of so many developments that all have the potential to kick the SP along significantly, namely:
1. Announcement of successful cap raising 2. Grant of Oraline import license to Mexico 3. Oraline order out of Mexico 4. Chinese government approval of SiYi's applications to manufacture and distribute Oraline in China 5. China's MPS commences Oraline field trials in 15 cities 6. Oraline8 launched 7. More US distributors signed up 8. Confirmed orders in Russia 9. Distribution partnerships in the UK and other western European countries 10. Results of Probeline trials
And just a couple of months after all that, the new urine-based products come into play.
With all that on the agenda - and with full ownership of IP and financial problems out of the way - it does seem short-sighted to sell at 1.2c.
But each to his own. Transfer of wealth, as always, from the impatient to the patient.
SBN Price at posting:
0.0¢ Sentiment: LT Buy Disclosure: Held